
Jan 6 (Reuters) - Denali Therapeutics Inc DNLI.O:
DENALI THERAPEUTICS ANNOUNCES KEY ANTICIPATED MILESTONES AND PRIORITIES FOR 2026 INCLUDING COMMERCIAL LAUNCH OF TIVIDENOFUSP ALFA FOR HUNTER SYNDROME
DENALI THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD ON DNL952, PHASE 1 STUDY TO PROCEED
DENALI THERAPEUTICS INC - PREPARES FOR FDA APPROVAL AND LAUNCH OF TIVIDENOFUSP ALFA